CLEAR COVID-19
The collaborative laboratories from the University Medical Center Utrecht (UMCU) and Vossensteyn Biomedical will develop a unique COVID-19 biobank, include viral isolates and nasal airway epithelial cells from patients, which will be used to quantitate in vitro characteristics related to virus-epithelium interactions, and to study correlations with mild or severe COVID-19 in patients. This will be done by assessment of viral replication and epithelial gene expression by single cell RNA sequencing. Additionally, nasal airway epithelial cell cultures will be used for large scale SARS-CoV-2 antiviral drug screening. Drugs of interests are published products and in-house FDA approved drugs (~1400 compounds), proprietary antimicrobial peptides with observed efficacy to SARS-CoV-2 pseudo-virus (Utrecht University) and various products with different modes-of-action from Vossensteyn Biomedical.
There is a high demand for SARS-CoV-2 antiviral therapies that may limit COVID-19 severity in susceptible individuals. At the end of March, Health~Holland set up
‘De exacte inhoud houden we geheim’ Geschreven door: Robbert Roos Gaan we de strijd tegen het Corona-virus winnen met een dampvloeistof? Als het aan Martijn
Clinically-validated nasal airway epithelial cell models for COVID-19 high throughput drug development The current COVID-19 pandemic has a strong impact on individual health and social
Vossensteyn Biomedical is a young startup with a revolutionary outlook. We have a different view on the medical and microbiological world. Together with doctors, immunologists, microbiologists, pharmacists and microchemists we are developing new medications and treatments for infectious diseases